ligandrol

Ligandrol, also known as LGD-4033, is a selective androgen receptor modulator (SARM) developed by Ligand Pharmaceuticals. It is investigated for potential medical uses such as treatment of muscle wasting and osteoporosis, but it is not approved for any medical indication in the United States or most other jurisdictions. LGD-4033 is non-steroidal and is designed to selectively stimulate anabolic activity in muscle and bone while aiming to minimize androgenic effects in other tissues.

Mechanism and research status: As a SARM, LGD-4033 binds to androgen receptors and is intended to produce muscle and bone benefits with a reduced risk of traditional androgenic side effects. Early-phase clinical trials have explored its effects on lean body mass, strength, and safety in healthy adults and older individuals. Results from small studies have shown increases in lean mass in some participants, but data are limited and not sufficient to establish efficacy, dosing, or long-term safety.

Regulatory and safety considerations: LGD-4033 is not approved for medical use and is not legal as a dietary supplement or therapeutic product in many regions. It is listed on the World Anti-Doping Agency (WADA) prohibited list and is banned in competitive sports. Safety concerns include suppression of natural testosterone production, potential alterations in lipid profiles, and uncertain long-term effects. Because of limited clinical data and the potential for adverse hormonal and metabolic effects, its use outside approved research is discouraged. Product quality and purity can also be variable in unregulated markets.